[You may also click here for additional information] NEW YORK, Nov. 21, 2025 /PRNewswire/ --Â Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. ("aTyr" or the "Company") (NASDAQ: ATYR) and reminds investors of the December 8, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) F ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Ardent (ARDT) To Contact Him Directly To Discuss Their Options If you purchased or acquired Ardent stock and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recognized ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Firefly Aerospace Inc. due to allegations of misleading statements and operational issues that have negatively impacted the company's stock performance and investor confidence [2][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Firefly Aerospace to contact them regarding their legal options, particularly in light of a federal securities class action filed against the company [1][2]. - The deadline for investors to seek the role of lead plaintiff in the class action is January 12, 2026 [2]. Group 2: Financial Performance and Stock Impact - Firefly Aerospace conducted its IPO on August 7, 2025, selling 19.296 million shares at $45.00 per share [6]. - In its first earnings report as a public company on September 22, 2025, Firefly reported a loss of $80.3 million, or $5.78 per share, compared to a loss of $58.7 million, or $4.60 per share, in the same quarter of 2024 [7]. - Revenue for the second quarter of 2025 was $15.55 million, below analyst estimates of $17.25 million and down 26.2% year-over-year [7]. - The Spacecraft Solutions business segment reported revenue of only $9.2 million, representing a 49% year-over-year decrease [7]. - Following the earnings report, Firefly's stock price fell by $7.58 per share, or 15.31%, closing at $41.94 on September 23, 2025 [8]. - On September 29, 2025, Firefly disclosed a failure in the first stage of its Alpha Flight 7 rocket, leading to further concerns about the company's technology and commercial commitments [9][10]. - This news caused Firefly's stock price to drop by $7.66 per share, or 20.73%, closing at $29.30 on September 30, 2025 [10]. Group 3: Allegations Against Firefly - The complaint against Firefly alleges that the company overstated demand and growth prospects for its Spacecraft Solutions offerings and the operational readiness of its Alpha rocket program [5]. - It is claimed that these misrepresentations would likely have a material negative impact on the company once revealed, affecting the integrity of the Offering Documents and public statements made during the class period [5].

Core Viewpoint - Scott+Scott Attorneys at Law LLP is investigating Stride, Inc. for potentially issuing misleading statements and failing to disclose material information to investors, which may violate federal securities laws [1][3]. Company Overview - Stride, Inc. is an education management organization that offers online education as an alternative to traditional education for public school students, along with career learning programs [2]. Financial Performance - On October 28, 2025, Stride reported a financial outlook for fiscal year 2026 that did not meet analysts' expectations, citing issues with an upgraded online platform and a poor customer experience leading to higher withdrawal and lower conversion rates [3]. - Following the disappointing financial outlook, Stride's stock price plummeted by 54%, closing at $70.05 per share on October 29, 2025 [4].

Core Viewpoint - Scott+Scott Attorneys at Law LLP is investigating Fiserv, Inc. for potentially issuing misleading statements and failing to disclose material information to investors, which may violate federal securities laws [1][3]. Company Performance - Fiserv reported third-quarter earnings on October 29, 2025, with adjusted earnings of $2.04 per share, which fell short of analysts' expectations of $2.64 per share [3]. - The company revised its 2025 adjusted earnings forecast to a range of $8.50 to $8.60 per share, down from the previous forecast of $10.15 to $10.30 per share made in July 2025 [3]. - Following the earnings report, Fiserv's share price dropped significantly, reaching as low as $66.58 per share, a decline of approximately 47% from $126.17 per share on October 28, 2025, amid heavy trading volume [3]. Legal Investigation - The investigation by Scott+Scott focuses on whether Fiserv or its officers and directors misled investors or failed to disclose critical information [1]. - The firm specializes in representing clients harmed by securities law violations and has a strong track record in achieving significant settlements [5].

Core Points - Scott+Scott Attorneys at Law LLP is investigating Alvotech for potentially issuing misleading statements and failing to disclose material information to investors, which may violate federal securities laws [1] - Alvotech develops and manufactures biosimilar medicines, focusing on therapeutic areas such as autoimmune, eye, bone disorders, and cancer [2] - On November 2, 2025, Alvotech received a complete response letter (CRL) from the FDA regarding its Biologics License Application (BLA) for AVT05, a biosimilar candidate to Simponi®, indicating deficiencies that must be resolved before approval [3] - Following the FDA's announcement, Alvotech's stock price dropped approximately 34%, closing at $5.03 on November 3, 2025 [3]

SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- A new class action complaint has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) and certain of its top executives, significantly enlarging the alleged class period covered by the ongoing securities litigation. The new class action, King v. aTyr Pharma Inc., filed in the U.S. District Court for the Southern District of California on behalf of investors who suffered substantial losses, now seeks to represent all persons and entities who acquired aTyr Pharm ...

Core Viewpoint - BellRing Brands, Inc. is under investigation for potential violations of federal securities laws, with concerns that the company's reported sales growth may not reflect sustainable consumer demand but rather temporary inventory loading at retailers [1][3]. Company Overview - BellRing Brands operates in the convenient nutrition category, primarily known for its brands Premier Protein and Dymatize, which offer ready-to-drink protein shakes and powders [3]. Sales Performance - The company claimed that Premier Protein achieved an all-time high in household penetration and strong growth across all channels, attributed to distribution expansion and promotional activities [3]. - However, the actual sales growth may have been artificially inflated due to temporary trade inventory loading at key retailers [3]. Stock Price Reaction - Following the announcement on May 5, 2025, regarding reduced inventory levels at retailers, BellRing's stock price dropped by $13.96, or over 18%, from $77.34 to $63.38 per share [4]. - On August 4, 2025, after reporting disappointing quarterly consumption figures for Premier Protein RTD Shakes, the stock fell by $17.46, nearly 33%, from $53.64 to $36.18 per share [5].

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Camping World (CWH) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Camping World and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a national ...

Core Viewpoint - A new class action lawsuit has been filed against aTyr Pharma, Inc. and its executives, expanding the alleged class period for investors who suffered losses from November 7, 2024, to September 12, 2025, due to misleading statements about the drug Efzofitimod [1][2][4]. Group 1: Class Action Details - The lawsuit, King v. aTyr Pharma Inc., seeks to represent all individuals and entities who acquired aTyr Pharma securities during the expanded class period [2]. - The previous class period began in January 2025, making this expansion significant for investors who purchased shares in late 2024 [2]. - The lead plaintiff deadline for the class action is set for December 8, 2025 [4]. Group 2: Allegations Against aTyr Pharma - The allegations center around aTyr's Phase 3 clinical trial, EFZO-FIT, which evaluated the drug Efzofitimod for patients with pulmonary sarcoidosis [5]. - Executives allegedly made overly positive statements about the drug's efficacy while concealing material adverse facts regarding its ability to reduce steroid dependency [6][7]. - The lawsuit claims that these misrepresentations constitute securities law violations, misleading investors about the drug's true prospects [7]. Group 3: Impact of the Allegations - The truth about the drug's efficacy was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to a significant drop in stock price [8][9]. - Following the announcement, aTyr's stock plummeted from $6.03 to $1.02 per share, marking an 83.2% decline in a single day [9]. - The company acknowledged the setback and indicated plans to engage with the FDA for a path forward [9]. Group 4: Investigation and Legal Support - Hagens Berman, a prominent shareholders rights firm, is investigating whether aTyr misled investors regarding the drug's data and trial design [10]. - The firm encourages investors who suffered losses to submit their claims and offers support for whistleblowers with non-public information [11].